Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Depreciation and Depletion (2016 - 2023)

Historic Depreciation and Depletion for Rocket Pharmaceuticals (RCKT) over the last 8 years, with Q3 2023 value amounting to $1.2 million.

  • Rocket Pharmaceuticals' Depreciation and Depletion rose 909.09% to $1.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was $4.6 million, marking a year-over-year increase of 2639.76%. This contributed to the annual value of $426000.0 for FY2019, which is 2909.09% up from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Depreciation and Depletion stood at $1.2 million for Q3 2023, which was up 909.09% from $1.2 million recorded in Q2 2023.
  • In the past 5 years, Rocket Pharmaceuticals' Depreciation and Depletion ranged from a high of $1.2 million in Q2 2023 and a low of $100000.0 during Q2 2019
  • In the last 5 years, Rocket Pharmaceuticals' Depreciation and Depletion had a median value of $767000.0 in 2022 and averaged $601769.2.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first changed by 0.0% in 2019, then soared by 4797.91% in 2023.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Depreciation and Depletion stood at $101000.0 in 2019, then decreased by 0.99% to $100000.0 in 2020, then soared by 700.0% to $800000.0 in 2021, then soared by 37.5% to $1.1 million in 2022, then grew by 9.09% to $1.2 million in 2023.
  • Its last three reported values are $1.2 million in Q3 2023, $1.2 million for Q2 2023, and $1.1 million during Q1 2023.